The activation of MAPK (particularly the ERK/MEK pathway) is associated with the development of CRPC and decreased survival for PCa patients (Mukherjee et al., 2011; Rodriguez‐Berriguete et al., 2012). The gene discussed is MAPK1; the disease is posterior cortical atrophy.